Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case

Repurposing and repositioning drugs has become a frequently pursued and successful strategy in the current era, as new chemical entities are increasingly difficult to find and get approved. Herein we report an integrated BioGPS/FLAPdock pipeline for rapid and effective off‐target identification and drug repurposing. Our method is based on the structural and chemical properties of protein binding sites, that is, the ligand image, encoded in the GRID molecular interaction fields (MIFs). Protein similarity is disclosed through the BioGPS algorithm by measuring the pockets’ overlap according to which pockets are clustered. Co‐crystallized and known ligands can be cross‐docked among similar targets, selected for subsequent in vitro binding experiments, and possibly improved for inhibitory potency. We used human thymidylate synthase (TS) as a test case and searched the entire RCSB Protein Data Bank (PDB) for similar target pockets. We chose casein kinase IIα as a control and tested a series of its inhibitors against the TS template. Ellagic acid and apigenin were identified as TS inhibitors, and various flavonoids were selected and synthesized in a second‐round selection. The compounds were demonstrated to be active in the low‐micromolar range.

[1]  Yoshihiro Yamanishi,et al.  Relating drug–protein interaction network with drug side effects , 2012, Bioinform..

[2]  Jian Wang,et al.  In Silico Elucidation of the Molecular Mechanism Defining the Adverse Effect of Selective Estrogen Receptor Modulators , 2007, PLoS Comput. Biol..

[3]  D. Santi,et al.  The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.

[4]  Raymond Lo,et al.  Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. , 2012, International journal of antimicrobial agents.

[5]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[6]  M. Mori,et al.  Histone demethylating agents as potential S-adenosyl-L-methionine-competitors , 2016 .

[7]  Stefano Alcaro,et al.  A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins , 2015, J. Chem. Inf. Model..

[8]  A. Bairoch,et al.  The SWISS-PROT protein sequence data bank: current status. , 1994, Nucleic acids research.

[9]  Weijun Xu,et al.  Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 , 2015, J. Chem. Inf. Model..

[10]  Paul T. Groth,et al.  Drug discovery FAQs: workflows for answering multidomain drug discovery questions. , 2015, Drug discovery today.

[11]  S. Moro,et al.  Toward the rational design of protein kinase casein kinase-2 inhibitors. , 2002, Pharmacology & therapeutics.

[12]  G. Peters,et al.  The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells , 2014, Cancer Chemotherapy and Pharmacology.

[13]  Philip E. Bourne,et al.  The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications , 2010, PLoS Comput. Biol..

[14]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[15]  F. Spyrakis,et al.  Expanding the chemical space of human serine racemase inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[16]  Gabriele Cruciani,et al.  Modeling Phospholipidosis Induction: Reliability and Warnings , 2013, J. Chem. Inf. Model..

[17]  Bin Chen,et al.  Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..

[18]  Nathanael Weill,et al.  Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..

[19]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[20]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[21]  Giorgio Palù,et al.  Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase , 2012, Proceedings of the National Academy of Sciences.

[22]  Keunwan Park,et al.  Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. , 2009, Molecular bioSystems.

[23]  Maria Paola Costi,et al.  Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. , 2010, Bioorganic & medicinal chemistry.

[24]  Dusanka Janezic,et al.  ProBiS algorithm for detection of structurally similar protein binding sites by local structural alignment , 2010, Bioinform..

[25]  Stéphanie Pérot,et al.  Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.

[26]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[27]  Maria Paola Costi,et al.  The inhibition of extended spectrum β-lactamases: hits and leads. , 2014, Current medicinal chemistry.

[28]  Zhongming Zhao,et al.  Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology , 2016, Scientific Reports.

[29]  H. Wolfson,et al.  Recognition of Functional Sites in Protein Structures☆ , 2004, Journal of Molecular Biology.

[30]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[31]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[32]  Gabriele Ausiello,et al.  Structural motifs recurring in different folds recognize the same ligand fragments , 2009, BMC Bioinformatics.

[33]  Laetitia Martin-Chanas,et al.  Identify drug repurposing candidates by mining the Protein Data Bank , 2011, Briefings Bioinform..

[34]  Edward Chu,et al.  Thymidylate synthase inhibitors as anticancer agents: from bench to bedside , 2003, Cancer Chemotherapy and Pharmacology.

[35]  L. Lebioda,et al.  Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. , 2001, Biochemistry.

[36]  Wolfgang Guba,et al.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.

[37]  John P. Overington,et al.  PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains , 2014, Bioinform..

[38]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[39]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[40]  Kalidas Yeturu,et al.  PocketMatch: A new algorithm to compare binding sites in protein structures , 2008, BMC Bioinformatics.

[41]  Lydia Siragusa,et al.  BioGPS Descriptors for Rational Engineering of Enzyme Promiscuity and Structure Based Bioinformatic Analysis , 2014, PloS one.

[42]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[43]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[44]  Roded Sharan,et al.  An Algorithmic Framework for Predicting Side Effects of Drugs , 2011, J. Comput. Biol..

[45]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[46]  Pietro Cozzini,et al.  Isozyme-Specific Ligands for O-acetylserine sulfhydrylase, a Novel Antibiotic Target , 2013, PloS one.

[47]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[48]  Stefan Schmitt,et al.  Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.

[49]  Lydia Siragusa,et al.  BioGPS: The Music for the Chemo‐ and Bioinformatics Walzer , 2014, Molecular informatics.

[50]  Andrew L. Hopkins,et al.  Drug discovery: Predicting promiscuity , 2009, Nature.

[51]  Russ B. Altman,et al.  Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding , 2011, PLoS Comput. Biol..

[52]  Russ B Altman,et al.  PharmGKB: a logical home for knowledge relating genotype to drug response phenotype , 2007, Nature Genetics.

[53]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[54]  Yoshihiro Yamanishi,et al.  DINIES: drug–target interaction network inference engine based on supervised analysis , 2014, Nucleic Acids Res..

[55]  David W. Ritchie,et al.  GESSE: Predicting Drug Side Effects from Drug-Target Relationships , 2015, J. Chem. Inf. Model..

[56]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  Patrick Aloy,et al.  Analysis of chemical and biological features yields mechanistic insights into drug side effects. , 2013, Chemistry & biology.

[58]  T K Attwood,et al.  OWL--a non-redundant composite protein sequence database. , 1994, Nucleic acids research.

[59]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[60]  L. Goracci,et al.  New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens. , 2013, European journal of medicinal chemistry.

[61]  Ziding Zhang,et al.  Similarity networks of protein binding sites , 2005, Proteins.

[62]  Maria Paola Costi,et al.  Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. , 2012, Journal of medicinal chemistry.

[63]  W. Pearson Rapid and sensitive sequence comparison with FASTP and FASTA. , 1990, Methods in enzymology.

[64]  Regina Z. Cer,et al.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..

[65]  G. Cruciani,et al.  Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. , 2004, Journal of medicinal chemistry.

[66]  Gergely Zahoránszky-Köhalmi,et al.  Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..

[67]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[68]  L. Pinna,et al.  Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. , 1997, Progress in cell cycle research.

[69]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[70]  G. Klebe,et al.  A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.

[71]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[72]  L. Goracci,et al.  Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses , 2012, Antimicrobial Agents and Chemotherapy.

[73]  Maria Paola Costi,et al.  Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase , 2011, Proceedings of the National Academy of Sciences.

[74]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[75]  Pietro Cozzini,et al.  Targeting Cystalysin, a Virulence Factor of Treponema denticola‐Supported Periodontitis , 2014, ChemMedChem.

[76]  Maria Paola Costi,et al.  Antibacterial agent discovery using thymidylate synthase biolibrary screening. , 2006, Journal of medicinal chemistry.

[77]  Jie Li,et al.  Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..

[78]  Tudor I. Oprea,et al.  Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.

[79]  L. Goracci,et al.  Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. , 2015, European journal of medicinal chemistry.

[80]  Michael Schroeder,et al.  Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key , 2013, PloS one.

[81]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[82]  D. Fairlie,et al.  Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets. , 2015, Journal of molecular graphics & modelling.

[83]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[84]  Gabriele Cruciani,et al.  BioGPS: Navigating biological space to predict polypharmacology, off‐targeting, and selectivity , 2015, Proteins.

[85]  Maria Paola Costi,et al.  Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine. , 2005, Journal of medicinal chemistry.